BMS 754807: Clinical Trials

3 trials of BMS 754807, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 terminated, 1 completed. 3 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 23Terminated 2, Completed 1
Phase 12Completed 1, Terminated 1

Follow BMS 754807: new trials by email Literature Review of BMS 754807 trials Research Report on BMS 754807

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
BMS-754807, letrozole - Breast Cancer
Phase 2TerminatedBristol-Myers Squibb772010-12-312020-08-11
Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors
BMS-754807, cetuximab (Erbitux®) - Colorectal Cancer, Head and Neck Cancer
Phase 1 / Phase 2TerminatedBristol-Myers Squibb542009-10-012013-06-18
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
BMS-754807, trastuzumab (Herceptin®) - Breast Cancer
Phase 1 / Phase 2CompletedBristol-Myers Squibb402009-07-012012-07-13

Conditions studied

Breast Neoplasms (2)  ·  Colorectal Neoplasms (1)  ·  Head and Neck Neoplasms (1)  ·  Neoplasm Metastasis (1)

Sponsors

Bristol-Myers Squibb (3)

Countries

Canada (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Hungary (1)  ·  United Kingdom (1)